Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 26, Issue 10, Pages 1131-1136
Publisher
Informa UK Limited
Online
2017-08-18
DOI
10.1080/13543784.2017.1369527
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50–95 years: a cross-sectional study
- (2017) Clifford R Jack et al. LANCET NEUROLOGY
- Identification of genes associated with dissociation of cognitive performance and neuropathological burden: Multistep analysis of genetic, epigenetic, and transcriptional data
- (2017) Charles C. White et al. PLOS MEDICINE
- The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
- (2016) Jeff Sevigny et al. NATURE
- The BACE1 inhibitor verubecestat (MK-8931) reduces CNS -amyloid in animal models and in Alzheimers disease patients
- (2016) M. E. Kennedy et al. Science Translational Medicine
- The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central A Pharmacodynamic Responses in Mice, Dogs, and Humans
- (2015) P. C. May et al. JOURNAL OF NEUROSCIENCE
- The Normal and Pathologic Roles of the Alzheimer's β-secretase, BACE1
- (2014) Patty Kandalepas et al. Current Alzheimer Research
- Tau deletion impairs intracellular β-amyloid-42 clearance and leads to more extracellular plaque deposition in gene transfer models
- (2014) Irina Lonskaya et al. Molecular Neurodegeneration
- Comparable brain levels of amyloid-β and tau in asymptomatic AD and mild cognitive impairment
- (2014) Nature Reviews Neurology
- Genetic Inhibition of Phosphorylation of the Translation Initiation Factor eIF2α Does Not Block Aβ-Dependent Elevation of BACE1 and APP Levels or Reduce Amyloid Pathology in a Mouse Model of Alzheimer’s Disease
- (2014) Katherine R. Sadleir et al. PLoS One
- BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
- (2014) Robert Vassar Alzheimers Research & Therapy
- The Alzheimer’s β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques
- (2013) Patty C. Kandalepas et al. ACTA NEUROPATHOLOGICA
- Bace1 and Neuregulin-1 cooperate to control formation and maintenance of muscle spindles
- (2013) Cyril Cheret et al. EMBO JOURNAL
- Increased Expression of Reticulon 3 in Neurons Leads to Reduced Axonal Transport of β Site Amyloid Precursor Protein-cleaving Enzyme 1
- (2013) Minzi Deng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Blood–brain-barriers in aging and in Alzheimer’s disease
- (2013) Fernanda Marques et al. Molecular Neurodegeneration
- BACE1 Regulates Hippocampal Astrogenesis via the Jagged1-Notch Pathway
- (2013) Xiangyou Hu et al. Cell Reports
- The Genetics of Alzheimer Disease
- (2013) R. E. Tanzi Cold Spring Harbor Perspectives in Medicine
- Amyloid imaging and cognitive decline in nondemented oldest-old: The 90+ Study
- (2012) Claudia H. Kawas et al. Alzheimers & Dementia
- Origins of Alzheimerʼs disease
- (2012) Erik S. Musiek et al. CURRENT OPINION IN NEUROLOGY
- β-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment
- (2012) Jun Cai et al. EMBO Molecular Medicine
- Small-molecule BACE1 inhibitors: a patent literature review (2006 – 2011)
- (2012) Gary Probst et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Cdk5 Protein Inhibition and Aβ42 Increase BACE1 Protein Level in Primary Neurons by a Post-transcriptional Mechanism
- (2012) Katherine R. Sadleir et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- β-Site Amyloid Precursor Protein (APP)-cleaving Enzyme 1 (BACE1)-deficient Mice Exhibit a Close Homolog of L1 (CHL1) Loss-of-function Phenotype Involving Axon Guidance Defects
- (2012) Brian Hitt et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Sorting nexin 12 interacts with BACE1 and regulates BACE1-mediated APP processing
- (2012) Yonghao Zhao et al. Molecular Neurodegeneration
- BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and β-amyloid production in Alzheimer’s disease
- (2012) Linda Chami et al. Molecular Neurodegeneration
- A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
- (2012) Thorlakur Jonsson et al. NATURE
- Alzheimer disease pathology and longitudinal cognitive performance in the oldest-old with no dementia
- (2012) A. B. Balasubramanian et al. NEUROLOGY
- Beneficial Effect of Antibodies against β- Secretase Cleavage Site of App on Alzheimer’s-Like Pathology in Triple-Transgenic Mice
- (2012) Inna Rabinovich-Nikitin et al. PLoS One
- Alzheimer Disease: New Concepts on Its Neurobiology and the Clinical Role Imaging Will Play
- (2012) Clifford R. Jack RADIOLOGY
- The precision of axon targeting of mouse olfactory sensory neurons requires the BACE1 protease
- (2012) Luxiang Cao et al. Scientific Reports
- Neocortical and hippocampal amyloid-β and tau measures associate with dementia in the oldest-old
- (2011) John L. Robinson et al. BRAIN
- Inhibition of β-Secretasein Vivovia Antibody Binding to Unique Loops (D and F) of BACE1
- (2011) Lujia Zhou et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Robust Central Reduction of Amyloid- in Humans with an Orally Available, Non-Peptidic -Secretase Inhibitor
- (2011) P. C. May et al. JOURNAL OF NEUROSCIENCE
- The Alzheimer's β-secretase enzyme BACE1 is required for accurate axon guidance of olfactory sensory neurons and normal glomerulus formation in the olfactory bulb
- (2011) Tharinda W Rajapaksha et al. Molecular Neurodegeneration
- A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid- Production in Vivo
- (2011) J. K. Atwal et al. Science Translational Medicine
- Alzheimer's Disease: The Challenge of the Second Century
- (2011) D. M. Holtzman et al. Science Translational Medicine
- β-Amyloid1–42Gene Transfer Model Exhibits Intraneuronal Amyloid, Gliosis, Tau Phosphorylation, and Neuronal Loss
- (2010) G. William Rebeck et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Genetic Causes of Frontotemporal Degeneration
- (2010) Tricia M. See et al. JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY
- Inhibiting β-Secretase Activity in Alzheimer's Disease Cell Models with Single-Chain Antibodies Specifically Targeting APP
- (2010) Shanta Boddapati et al. JOURNAL OF MOLECULAR BIOLOGY
- BACE1 Deficiency Causes Altered Neuronal Activity and Neurodegeneration
- (2010) X. Hu et al. JOURNAL OF NEUROSCIENCE
- BACE1-/- mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization
- (2010) Brian D. Hitt et al. Molecular Neurodegeneration
- An Amyloid-Notch Hypothesis for Alzheimer’s Disease
- (2010) Douglas W. Ethell NEUROSCIENTIST
- Tau Reduction Prevents Aβ-Induced Defects in Axonal Transport: Fig. 1
- (2010) Keith A. Vossel et al. SCIENCE
- The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism
- (2009) Raphael Kopan et al. CELL
- Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves
- (2008) Xiangyou Hu et al. FASEB JOURNAL
- Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice
- (2008) A. V. Savonenko et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BACE1 gene deletion: Impact on behavioral function in a model of Alzheimer's disease
- (2007) Dione Kobayashi et al. NEUROBIOLOGY OF AGING
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now